ArticleBladder cancer (Amsterdam, Netherlands)2018
Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract.
Article in Bladder cancer (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07077447 (DaBlaCa 23 - The European Collaborative Study on Upper Urinary Tract Urothelial Carcinoma), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DaBlaCa 23 - The European Collaborative Study on Upper Urinary Tract Urothelial Carcinoma
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Institutional adherence, complication rates, and intravesical recurrence with intraoperative mitomycin C during radical nephroureterectomy.International urology and nephrology · 2026Article
- Strategies to reduce bladder tumor recurrences following surgery for upper tract urothelial carcinoma.Bladder (San Francisco, Calif.) · 2024Article
- Single instillation intravesical chemotherapy after radical nephroureterectomy for upper tract urothelial carcinoma: current evidence and future directions.Translational andrology and urology · 2023Review
- Intravesical Therapy for Upper Urinary Tract Urothelial Carcinoma: A Comprehensive Review.Cancers · 2023Review
- Immediate gemcitabine bladder instillation following bladder closure during robotic-assisted radical nephroureterectomy: a multi-institutional report of feasibility and initial outcomes.Translational andrology and urology · 2023Article
- Clinical Characteristics and Current Status of Treatment for Recurrent Bladder Cancer after Surgeries on Upper Tract Urothelial Carcinoma.Diagnostics (Basel, Switzerland) · 2023Review
- Robotic nephroureterectomy in the management of upper tract urothelial cancer: inching toward standard of care?International urology and nephrology · 2022Review
- Assessment of Therapeutic Benefit and Option Strategy on Intravesical Instillation for Preventing Bladder Cancer Recurrence after Radical Nephroureterectomy in Patients with Upper Urinary Tract Urothelial Carcinoma.Journal of oncology · 2022Article
- Intraoperative Mitomycin C Bladder Instillation During Radical Nephroureterectomy Is Feasible and Safe.European urology open science · 2021Article
- The nephroureterectomy: a review of technique and current controversies.Translational andrology and urology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResults of randomized trials support a single dose of intravesical chemotherapy following radical nephroureterectomy (RNU) for urothelial carcinoma.
objectiveTo evaluate the impact of the timing of intravesical mitomycin C (MMC) administration on the rate of bladder tumor recurrence (BTR) following RNU.
methodsWe performed a retrospective review of patients who underwent RNU for upper tract urothelial carcinoma (UTUC) and received intravesical MMC between 2008 and 2016. Patients were categorized into two separate groups based on the timing of MMC administration: patients who received MMC intraoperatively (IO) and patients who received MMC on post-operative day 1 or later (PO). Our primary endpoint was BTR rate within the first year after surgery.
resultsFifty-one patients met our inclusion criteria: (IO:
conclusionsThe use of intraoperative MMC at the time of RNU was associated with a decrease in the risk of 1-year recurrence within the bladder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.